Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
The unique biological dataset combined with a new CellularAI algorithm wins
"The Billion Cell Atlas is quickly becoming a foundational dataset that we believe can help advance the field toward a future of predictive biology," said
The Billion Cell Atlas is the world's largest genome-wide genetic perturbation dataset, capturing how individual cells respond to genetic changes via CRISPR across more than 200 disease-relevant cell lines. The data is being generated by
Researchers will be able to observe perturbation responses at scale with their data, predict responses in cell types that have not yet been experimentally tested with CellularAI, and test resulting hypotheses experimentally through direct CRISPR capture capabilities in the Illumina Single Cell Preparation workflow. Together, the data and the CellularAI algorithm can unlock a broad range of applications, including validating targets from human genetics, modeling disease-relevant cell types and conditions, and elucidating drug mechanisms of action.
The 2026 Virtual Cell Challenge, hosted by
Learn more about CellularAI here.
Learn more about how
Use of Forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, validating, and advancing artificial intelligence models and related technologies, including CellularAI; (ii) our ability to realize the anticipated benefits and potential applications of the Billion Cell Atlas, CellularAI, and other artificial intelligence technologies, including their potential to advance biological research and drug discovery; and (iii) the performance, utility, acceptance, and adoption of CellularAI and related technologies, which may or may not meet our expectations and those of researchers and customers, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation and do not intend to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-wins-virtual-cell-challenge-powered-by-billion-cell-atlas-302946270.html
SOURCE Illumina, Inc.